Qizhi Kebitong Formula Ameliorates Streptozocin-Induced Diabetic Osteoporosis through Regulating the PI3K/Akt/NF-
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
03
2022
revised:
22
06
2022
accepted:
15
07
2022
entrez:
1
9
2022
pubmed:
2
9
2022
medline:
8
9
2022
Statut:
epublish
Résumé
Diabetic osteoporosis (DOP) is a progressive osteoblast dysfunction induced by high glucose, which has negative impacts on bone homeostasis. Qizhi Kebitong formula (QKF) is a traditional Chinese medicine (TCM) formula for treating DOP. However, its role in the protection of DOP has not been clarified yet. Here, we aimed to explore the potential mechanisms of QKF on DOP development via Network pharmacology was used to detect the key targets and signaling pathways of QKF on DOP. The effects of QKF on DOP were examined by the phenotypic characteristics, micro-CT, and hematoxylin-eosin (H&E) staining. The predicted targets and pathways were validated by a streptozocin- (STZ-) induced mouse model. Subsequently, the levels of the selected genes and proteins were analyzed using qRT-PCR and Western blot. Finally, AutoDock and PyMOL were used for molecular docking. In this study, 90 active compounds and 2970 related disease targets have been found through network pharmacology. And QKF could improve the microstructures of femur bone mass, reduce inflammatory cell infiltration, and downregulate the levels of TNF- Altogether, our findings suggested that QKF could markedly alleviate osteoblast dysfunction by modulating the key targets and PI3K/Akt/NF-
Sections du résumé
Background
UNASSIGNED
Diabetic osteoporosis (DOP) is a progressive osteoblast dysfunction induced by high glucose, which has negative impacts on bone homeostasis. Qizhi Kebitong formula (QKF) is a traditional Chinese medicine (TCM) formula for treating DOP. However, its role in the protection of DOP has not been clarified yet. Here, we aimed to explore the potential mechanisms of QKF on DOP development via
Methods
UNASSIGNED
Network pharmacology was used to detect the key targets and signaling pathways of QKF on DOP. The effects of QKF on DOP were examined by the phenotypic characteristics, micro-CT, and hematoxylin-eosin (H&E) staining. The predicted targets and pathways were validated by a streptozocin- (STZ-) induced mouse model. Subsequently, the levels of the selected genes and proteins were analyzed using qRT-PCR and Western blot. Finally, AutoDock and PyMOL were used for molecular docking.
Results
UNASSIGNED
In this study, 90 active compounds and 2970 related disease targets have been found through network pharmacology. And QKF could improve the microstructures of femur bone mass, reduce inflammatory cell infiltration, and downregulate the levels of TNF-
Conclusion
UNASSIGNED
Altogether, our findings suggested that QKF could markedly alleviate osteoblast dysfunction by modulating the key targets and PI3K/Akt/NF-
Identifiants
pubmed: 36046447
doi: 10.1155/2022/4469766
pmc: PMC9420605
doi:
Substances chimiques
Drugs, Chinese Herbal
0
NF-kappa B
0
Streptozocin
5W494URQ81
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4469766Informations de copyright
Copyright © 2022 Lulu Tian et al.
Déclaration de conflit d'intérêts
The authors declare that there were no conflicts of interest regarding the publication of this paper.
Références
Pharmazie. 2016 Mar;71(3):134-8
pubmed: 27183707
Evid Based Complement Alternat Med. 2021 Jun 11;2021:5590743
pubmed: 34194519
J Cell Mol Med. 2022 Apr;26(8):2163-2176
pubmed: 35181992
Front Immunol. 2022 Jan 20;12:758829
pubmed: 35126350
Oxid Med Cell Longev. 2022 Jan 17;2022:2634431
pubmed: 35082963
J Tradit Chin Med. 2019 Feb;39(1):133-138
pubmed: 32186034
Aging (Albany NY). 2021 Jul 1;13(13):17370-17379
pubmed: 34198266
Evid Based Complement Alternat Med. 2015;2015:514063
pubmed: 26557149
Environ Sci Pollut Res Int. 2020 Jun;27(17):20950-20961
pubmed: 32253695
J Diabetes Investig. 2022 Feb;13(2):236-248
pubmed: 34739190
Drug Des Devel Ther. 2015 Sep 09;9:5169-83
pubmed: 26392752
Cell Physiol Biochem. 2017;43(4):1547-1561
pubmed: 29035884
Mol Brain. 2016 Feb 03;9:12
pubmed: 26842559
Maturitas. 2008 Dec 20;61(4):334-9
pubmed: 19004583
Food Funct. 2021 Nov 29;12(23):11898-11912
pubmed: 34739010
Transplantation. 2017 Jan;101(1):32-44
pubmed: 27547870
Biomed Pharmacother. 2019 Sep;117:109102
pubmed: 31228802
Mol Cell Endocrinol. 2022 Apr 15;546:111559
pubmed: 35051552
Nat Rev Endocrinol. 2021 Nov;17(11):685-697
pubmed: 34518671
J Bone Miner Metab. 2022 Mar;40(2):208-219
pubmed: 34750680
Connect Tissue Res. 2022 Feb 17;:1-13
pubmed: 35175165
Lancet Diabetes Endocrinol. 2022 Mar;10(3):207-220
pubmed: 35101185
Mol Cell Biol. 2012 Jan;32(2):490-500
pubmed: 22064480
Curr Osteoporos Rep. 2021 Feb;19(1):50-57
pubmed: 33432548
Nature. 2003 May 15;423(6937):316-8
pubmed: 12748648
Molecules. 2021 Oct 28;26(21):
pubmed: 34770916
Toxicology. 2004 Oct 15;203(1-3):199-209
pubmed: 15363595
Evid Based Complement Alternat Med. 2022 Feb 08;2022:4093138
pubmed: 35178102
Evid Based Complement Alternat Med. 2021 Oct 05;2021:6480381
pubmed: 34650613
Evid Based Complement Alternat Med. 2022 Feb 3;2022:6741995
pubmed: 35154351
Curr Opin Endocrinol Diabetes Obes. 2021 Aug 1;28(4):360-370
pubmed: 34183538
Curr Osteoporos Rep. 2020 Dec;18(6):796-802
pubmed: 33184775
Bioengineered. 2022 Mar;13(3):5581-5597
pubmed: 35184684
J Ethnopharmacol. 2020 Apr 6;251:112542
pubmed: 31904494
Aging Clin Exp Res. 2022 Jan;34(1):121-127
pubmed: 34050917
Front Pharmacol. 2021 Jun 14;12:697442
pubmed: 34220521
Eur J Pharmacol. 2015 Oct 15;765:394-401
pubmed: 26362750
Int J Oral Maxillofac Implants. 2013 Sep-Oct;28(5):1386-94
pubmed: 24066332
Toxicon. 2009 Jan;53(1):60-8
pubmed: 18984001
Arch Pharm Res. 2003 Nov;26(11):917-24
pubmed: 14661857
J Nutr Biochem. 2022 Jun;104:108973
pubmed: 35196574
Pak J Pharm Sci. 2018 May;31(3(Special)):1151-1156
pubmed: 29735466